| Identification | Back Directory | [Name]
ACHN 490 | [CAS]
1154757-24-0 | [Synonyms]
ACHN 490
PlazoMicin
Plazomicin API
IYDYFVUFSPQPPV-BPUQVFSTSA-N
O-2-AMino-2,3,4,6-tetradeoxy-6-[(2-hydroxyethyl)aMino]-α-D-glycero-hex-4-enopyranosyl-(1→4)-O-[3-deoxy-4-C-Methyl-3-(MethylaMino)-β-L-arabinopyranosyl-(1→6)]-N1-[(2S)-4-aMino-2-hydroxy-1-oxobutyl]-2-deoxy-D-streptaMine
D-Streptamine, O-2-amino-2,3,4,6-tetradeoxy-6-[(2-hydroxyethyl)amino]-α-D-glycero-hex-4-enopyranosyl-(1→4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy- | [Molecular Formula]
C25H48N6O10 | [MDL Number]
MFCD30533406 | [MOL File]
1154757-24-0.mol | [Molecular Weight]
592.683 |
| Chemical Properties | Back Directory | [Melting point ]
>185°C (dec.) | [Boiling point ]
896.4±65.0 °C(Predicted) | [density ]
1.40±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Water (Slightly) | [form ]
Solid | [pka]
13.11±0.20(Predicted) | [color ]
Pale Yellow |
| Hazard Information | Back Directory | [Description]
Plazomicin (PLZ) is a novel aminoglycoside approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections (cUTI, including acute pyelonephritis) in adults due to multidrug-resistant carbapenem-resistant Enterobacterales (CRE) or extended-spectrum beta-lactamase (ESBL) producing bacteria. Despite the FDA Black Box Warning for aminoglycoside class effects, PLZ exhibited a favourable safety profile with decreased adverse effects in the largest in-human trials. In vitro, activity of PLZ, in comparison with that of other aminoglycosides, was found to be excellent, with 92.3% to 98.0% overall susceptibility in Enterobacterales, including CRE. Recently, PLZ was also shown to be active against certain multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens for which limited treatment options are left[1-2].
| [Uses]
Plazomicin is a neoglycoside antibiotic with activity against a broad range of Gram-positive and Gram-negive pathogens. Plazomicin showed potent in vitro activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli. | [Uses]
Plazomicin is a neoglycoside antibiotic with activity against a broad range of Gram-positive and Gram-negive pathogens. Plazomicin showed potent in vitro activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli. | [References]
[1] Kristy M Shaeer. “Plazomicin: A Next-Generation Aminoglycoside.” Pharmacotherapy 39 1 (2019): 77–93.
[2] Laurine S Blanchard. “Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales.” Journal of Clinical Microbiology 60 1 (2022): e0183121.
|
|
| Company Name: |
Lynnchem
|
| Tel: |
86-(0)29-85992781 17792393971 |
| Website: |
http://www.lynnchem.com/ |
| Company Name: |
Novachemistry
|
| Tel: |
44-20819178-90 02081917890 |
| Website: |
https://www.novachemistry.com/ |
|